MARKET

AARD

AARD

Aardvark Therapeutics
NASDAQ
1.150
-0.110
-8.73%
Pre Market: 1.235 +0.085 +7.37% 07:00 11/18 EST
OPEN
1.240
PREV CLOSE
1.260
HIGH
1.380
LOW
1.100
VOLUME
389
TURNOVER
--
52 WEEK HIGH
16.60
52 WEEK LOW
0.9300
MARKET CAP
25.17M
P/E (TTM)
-0.3452
1D
5D
1M
3M
1Y
5Y
1D
RBC Capital Sticks to Its Hold Rating for Aardvark Therapeutics, Inc. (AARD)
TipRanks · 1d ago
Weekly Report: what happened at AARD last week (1109-1113)?
Weekly Report · 2d ago
Analysts Offer Insights on NA Companies: Mobility Global Inc (MBGL) and Aardvark Therapeutics, Inc. (AARD)
TipRanks · 2d ago
Aardvark Therapeutics GAAP EPS of -$0.88
Seeking Alpha · 5d ago
Aardvark Therapeutics reports Q3 EPS (88c), consensus (75c)
TipRanks · 5d ago
*Aardvark Therapeutics 3Q Research & Development $15.7M >AARD
Dow Jones · 5d ago
*Aardvark Therapeutics 3Q Loss/Shr 88c >AARD
Dow Jones · 5d ago
Press Release: Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Dow Jones · 5d ago
More
About AARD
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).

Webull offers Aardvark Therapeutics, Inc. stock information, including NASDAQ: AARD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AARD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AARD stock methods without spending real money on the virtual paper trading platform.